← Leaderboards
Maximilian Diehn
Stanford University
$12,346,945
Attributed
$23,225,611
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,307,388 · 12
By mechanism
R01$17,900,858 · 7
P01$9,532,999 · 3
DP2$2,407,500 · 1
R44$1,466,031 · 1
Top collaborators
- Arash Ash Alizadeh25 shared
- Ruijiang Li7 shared
- Joseph C Liao5 shared
- Billy W Loo5 shared
- Quynh-Thu X Le4 shared
- Hanlee Ji2 shared
- Lucian Orbai2 shared
Most similar at Stanford University
Same institution · by research overlap
- Quynh-Thu X Le$15,492,013
- Erinn B Rankin$3,755,975
- David Matthew Kurtz$956,520
- Ronald Levy$27,846,042
- Matthew J. Frank$844,890
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCancer PatientMolecularRecurrenceCohortTumor DnaGenomicsMalignant NeoplasmsHigh RiskDiagnosisBloodClinical TrialsBiological MarkersResponseProspectiveMalignant Neoplasm Of LungPrediction Of Response To TherapyPersonalized MedicineMutationToxic EffectDoctor Of PhilosophyGenotypeMonitorNon-Small-Cell Lung Carcinoma
Grant awards (43)
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy$1,990,934
P01 · FY2025 · CA
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$653,978
R01 · FY2025 · CA
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy$627,344
R01 · FY2025 · CA
Project 3: Targeting KEAP1-Mediated Radioresistance in Lung Cancer$360,482
P01 · FY2025 · CA · contact PI
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy$1,922,740
P01 · FY2024 · CA
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy$627,705
R01 · FY2024 · CA
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$621,261
R01 · FY2024 · CA
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$597,876
R01 · FY2024 · CA · contact PI
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$559,757
R01 · FY2024 · CA · contact PI
Project 3: Targeting KEAP1-Mediated Radioresistance in Lung Cancer$346,954
P01 · FY2024 · CA · contact PI
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy$2,021,847
P01 · FY2023 · CA
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$640,898
R01 · FY2023 · CA
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$616,757
R01 · FY2023 · CA · contact PI
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$585,127
R01 · FY2023 · CA · contact PI
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$548,151
R01 · FY2023 · CA
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$537,646
R01 · FY2023 · CA
Project 3: Targeting KEAP1-Mediated Radioresistance in Lung Cancer$363,155
P01 · FY2023 · CA · contact PI
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy$2,146,256
P01 · FY2022 · CA
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$640,898
R01 · FY2022 · CA
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$616,753
R01 · FY2022 · CA · contact PI
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$595,388
R01 · FY2022 · CA · contact PI
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$550,709
R01 · FY2022 · CA
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$537,646
R01 · FY2022 · CA
Project 3: Targeting KEAP1-Mediated Radioresistance in Lung Cancer$380,631
P01 · FY2022 · CA · contact PI
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$654,694
R01 · FY2021 · CA
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$632,011
R01 · FY2021 · CA · contact PI
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$618,012
R01 · FY2021 · CA · contact PI
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$561,946
R01 · FY2021 · CA
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$548,619
R01 · FY2021 · CA
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$641,101
R01 · FY2020 · CA · contact PI
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$625,866
R01 · FY2020 · CA · contact PI
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$561,946
R01 · FY2020 · CA
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$548,619
R01 · FY2020 · CA
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$561,946
R01 · FY2019 · CA
Imaging and circulating DNA markers to assess early response and predict treatment failure patterns in lung cancer$548,619
R01 · FY2019 · CA
Noninvasive monitoring of lung cancer patients treated with radiotherapy$356,081
R01 · FY2019 · CA · contact PI
Rescuing Nucleic Acids from Formalin Damage in Cancer Specimens$730,394
R44 · FY2018 · CA
Noninvasive monitoring of lung cancer patients treated with radiotherapy$367,095
R01 · FY2018 · CA · contact PI
Rescuing Nucleic Acids from Formalin Damage in Cancer Specimens$735,637
R44 · FY2017 · CA
Noninvasive monitoring of lung cancer patients treated with radiotherapy$367,095
R01 · FY2017 · CA · contact PI
Noninvasive monitoring of lung cancer patients treated with radiotherapy$372,645
R01 · FY2016 · CA · contact PI
Noninvasive monitoring of lung cancer patients treated with radiotherapy$376,669
R01 · FY2015 · CA · contact PI
Developing a genomic approach for cancer screening$2,407,500
DP2 · FY2013 · CA · contact PI